SAC Faces SEC Insider-Trading Probe On Biotech Merger

Jun 1 2011 | 4:49am ET

The Securities and Exchange Commission is zeroing in on SAC Capital Advisors in its investigation into possible insider trading of healthcare stocks.

SAC is the focus of a probe into trading around AstraZeneca's 2007 takeover of biotechnology firm MedImmune Inc. It is the third insider-trading investigation of the $14 billion hedge fund giant to emerge in recent months.


In Depth

Fund Focus: Don’t Call K1T Capital A ‘Trend Follower’

Jul 10 2014 | 10:39am ET

You may call K1T Capital many things—systematic, quant-based, hedge fund—but...

Lifestyle

RenTech Founder Donation Establishes Quantitative Biology Institute

Jul 8 2014 | 5:19am ET

James Simons used math to make his fortune, and he’s dedicating some of it to...

Guest Contributor

As Hedge Funds Go Retail, Communications Is Key

Jul 2 2014 | 6:56am ET

The past two years have seen an explosion in the number of hedge fund managers rolling...

 

Sponsored Content

    Northern Trust Helps Hedge Funds Navigate Derivatives Regulations

    Jul 8 2014 | 10:48am ET

    The surge in derivatives regulation is among the most complex challenges facing the financial services industry today. Northern Trust’s Joshua Satten recently spoke with FINalternatives to share insights into the challenges presented by new regulation and explore how the industry is responding. Read more…

Service Providers


Publisher's Note